Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. / The Respond Study Group.

In: HIV Medicine, Vol. 23, No. 8, 2022, p. 895-910.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

The Respond Study Group 2022, 'Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium', HIV Medicine, vol. 23, no. 8, pp. 895-910. https://doi.org/10.1111/hiv.13273

APA

The Respond Study Group (2022). Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Medicine, 23(8), 895-910. https://doi.org/10.1111/hiv.13273

Vancouver

The Respond Study Group. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Medicine. 2022;23(8):895-910. https://doi.org/10.1111/hiv.13273

Author

The Respond Study Group. / Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. In: HIV Medicine. 2022 ; Vol. 23, No. 8. pp. 895-910.

Bibtex

@article{26538cdf62b04c16a75ff77be1dda020,

title = "Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium",

abstract = "Objective: To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs) in the RESPOND consortium of HIV cohorts. Methods: Eligible people with HIV were aged ≥18 years who initiated a new three-drug ART regimen for the first time (baseline), did not have hypertension, and had at least two follow-up blood pressure (BP) measurements. Hypertension was defined as two consecutive systolic BP measurements ≥140 mmHg and/or diastolic BP ≥90 mmHg or initiation of antihypertensives. Multivariable Poisson regression was used to determine adjusted incidence rate ratios (aIRRs) of hypertension, overall and in those who were ART na{\"i}ve or experienced at baseline. Results: Overall, 4606 people living with HIV were eligible (INSTIs 3164, NNRTIs 807, PIs 635). The median baseline systolic BP, diastolic BP, and age were 120 (interquartile range [IQR] 113–130) mmHg, 78 (70–82) mmHg, and 43 (34–50) years, respectively. Over 8380.4 person-years (median follow-up 1.5 [IQR 1.0–2.7] years), 1058 (23.0%) participants developed hypertension (incidence rate 126.2/1000 person-years, 95% confidence interval [CI] 118.9–134.1). Participants receiving INSTIs had a higher incidence of hypertension than those receiving NNRTIs (aIRR 1.76; 95% CI 1.47–2.11), whereas the incidence was no different in those receiving PIs (aIRR 1.07; 95% CI 0.89–1.29). The results were similar when the analysis was stratified by ART status at baseline. Conclusion: Although unmeasured confounding and channelling bias cannot be excluded, INSTIs were associated with a higher incidence of hypertension than were NNRTIs, but rates were similar to those of PIs overall, in ART-na{\"i}ve and ART-experienced participants within RESPOND.",

keywords = "antiretroviral agents, HIV, hypertension, integrase inhibitors",

author = "Byonanebye, {Dathan M.} and Polizzotto, {Mark N.} and Bastian Neesgaard and Mario Sarcletti and Raimonda Matulionyte and Braun, {Dominique L.} and Antonella Castagna and {de Wit}, St{\'e}phane and Ferdinand Wit and Eric Fontas and J{\"o}rg Janne Vehreschild and Jan Vesterbacka and Lauren Greenberg and Camilla Hatleberg and Harmony Garges and Joel Gallant and {Volny Anne}, Alain and Angela {\"O}llinger and Iwona Mozer-Lisewska and Bernard Surial and Vincenzo Spagnuolo and Coca Necsoi and {van der Valk}, Marc and Amanda Mocroft and Matthew Law and Lene Ryom and Kathy Petoumenos and M. Hillebregt and N. Rose and J. Hutchinson and R. Zangerle and H. Appoyer and M. Delforge and C. Stephan and M. Bucht and N. Chkhartishvili and O. Chokoshvili and C. Mussini and C. Smith and M. Johnson and J. Lundgren and J. Kowalska and D. Raben and L. Peters and Larsen, {J. F.} and Jakobsen, {M. L.} and T. Bruun and A. Bojesen and Hansen, {E. V.} and D. Kristensen and {The Respond Study Group}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.",

year = "2022",

doi = "10.1111/hiv.13273",

language = "English",

volume = "23",

pages = "895--910",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell",

number = "8",

}

RIS

TY - JOUR

T1 - Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

AU - Byonanebye, Dathan M.

AU - Polizzotto, Mark N.

AU - Neesgaard, Bastian

AU - Sarcletti, Mario

AU - Matulionyte, Raimonda

AU - Braun, Dominique L.

AU - Castagna, Antonella

AU - de Wit, Stéphane

AU - Wit, Ferdinand

AU - Fontas, Eric

AU - Vehreschild, Jörg Janne

AU - Vesterbacka, Jan

AU - Greenberg, Lauren

AU - Hatleberg, Camilla

AU - Garges, Harmony

AU - Gallant, Joel

AU - Volny Anne, Alain

AU - Öllinger, Angela

AU - Mozer-Lisewska, Iwona

AU - Surial, Bernard

AU - Spagnuolo, Vincenzo

AU - Necsoi, Coca

AU - van der Valk, Marc

AU - Mocroft, Amanda

AU - Law, Matthew

AU - Ryom, Lene

AU - Petoumenos, Kathy

AU - Hillebregt, M.

AU - Rose, N.

AU - Hutchinson, J.

AU - Zangerle, R.

AU - Appoyer, H.

AU - Delforge, M.

AU - Stephan, C.

AU - Bucht, M.

AU - Chkhartishvili, N.

AU - Chokoshvili, O.

AU - Mussini, C.

AU - Smith, C.

AU - Johnson, M.

AU - Lundgren, J.

AU - Kowalska, J.

AU - Raben, D.

AU - Peters, L.

AU - Larsen, J. F.

AU - Jakobsen, M. L.

AU - Bruun, T.

AU - Bojesen, A.

AU - Hansen, E. V.

AU - Kristensen, D.

AU - The Respond Study Group

PY - 2022

Y1 - 2022

N2 - Objective: To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs) in the RESPOND consortium of HIV cohorts. Methods: Eligible people with HIV were aged ≥18 years who initiated a new three-drug ART regimen for the first time (baseline), did not have hypertension, and had at least two follow-up blood pressure (BP) measurements. Hypertension was defined as two consecutive systolic BP measurements ≥140 mmHg and/or diastolic BP ≥90 mmHg or initiation of antihypertensives. Multivariable Poisson regression was used to determine adjusted incidence rate ratios (aIRRs) of hypertension, overall and in those who were ART naïve or experienced at baseline. Results: Overall, 4606 people living with HIV were eligible (INSTIs 3164, NNRTIs 807, PIs 635). The median baseline systolic BP, diastolic BP, and age were 120 (interquartile range [IQR] 113–130) mmHg, 78 (70–82) mmHg, and 43 (34–50) years, respectively. Over 8380.4 person-years (median follow-up 1.5 [IQR 1.0–2.7] years), 1058 (23.0%) participants developed hypertension (incidence rate 126.2/1000 person-years, 95% confidence interval [CI] 118.9–134.1). Participants receiving INSTIs had a higher incidence of hypertension than those receiving NNRTIs (aIRR 1.76; 95% CI 1.47–2.11), whereas the incidence was no different in those receiving PIs (aIRR 1.07; 95% CI 0.89–1.29). The results were similar when the analysis was stratified by ART status at baseline. Conclusion: Although unmeasured confounding and channelling bias cannot be excluded, INSTIs were associated with a higher incidence of hypertension than were NNRTIs, but rates were similar to those of PIs overall, in ART-naïve and ART-experienced participants within RESPOND.

AB - Objective: To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs) in the RESPOND consortium of HIV cohorts. Methods: Eligible people with HIV were aged ≥18 years who initiated a new three-drug ART regimen for the first time (baseline), did not have hypertension, and had at least two follow-up blood pressure (BP) measurements. Hypertension was defined as two consecutive systolic BP measurements ≥140 mmHg and/or diastolic BP ≥90 mmHg or initiation of antihypertensives. Multivariable Poisson regression was used to determine adjusted incidence rate ratios (aIRRs) of hypertension, overall and in those who were ART naïve or experienced at baseline. Results: Overall, 4606 people living with HIV were eligible (INSTIs 3164, NNRTIs 807, PIs 635). The median baseline systolic BP, diastolic BP, and age were 120 (interquartile range [IQR] 113–130) mmHg, 78 (70–82) mmHg, and 43 (34–50) years, respectively. Over 8380.4 person-years (median follow-up 1.5 [IQR 1.0–2.7] years), 1058 (23.0%) participants developed hypertension (incidence rate 126.2/1000 person-years, 95% confidence interval [CI] 118.9–134.1). Participants receiving INSTIs had a higher incidence of hypertension than those receiving NNRTIs (aIRR 1.76; 95% CI 1.47–2.11), whereas the incidence was no different in those receiving PIs (aIRR 1.07; 95% CI 0.89–1.29). The results were similar when the analysis was stratified by ART status at baseline. Conclusion: Although unmeasured confounding and channelling bias cannot be excluded, INSTIs were associated with a higher incidence of hypertension than were NNRTIs, but rates were similar to those of PIs overall, in ART-naïve and ART-experienced participants within RESPOND.

KW - antiretroviral agents

KW - HIV

KW - hypertension

KW - integrase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85127440255&partnerID=8YFLogxK

U2 - 10.1111/hiv.13273

DO - 10.1111/hiv.13273

M3 - Journal article

C2 - 35233903

AN - SCOPUS:85127440255

VL - 23

SP - 895

EP - 910

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 8

ER -

ID: 319532650

Forskning